HPV virus as the main cause of cervical cancer, vaccination - literature review
DOI:
https://doi.org/10.12775/JEHS.2023.13.03.038Keywords
HPV, HPV vaccine, cervical cancer, high-risk HPV, human papillomavirusAbstract
HPV infection is one of the most common viral infection of the female and male reproductive tract worldwide. Most of the human papillomavirus infections cause no symptoms and go away on their own. Some infections develop into persistent infection, which can lead to the development of cancer of the cervix, anogenital, oral cavity and pharynx.In this paper, we focused on cervical cancer, which is the second most common cancer in the world among women. More than 300,000 women died from this cancer in 2020. The invention and introduction of prophylactic HPV vaccines has played a significant role in reducing the number of viral infections, thus reducing the incidence of benign and malignant diseases caused by them and the mortality resulting from them. There are three vaccines on the pharmaceutical marketfor prevention of specific HPV infection. They are: a bivalent vaccine Cervarix, a tetravalent vaccine Gardasil and a nonavalent vaccine Gardasil 9. These vaccines are safe because they do not contain an attenuated virus particle, but their production is based on a virus-like particle of the main capsid protein L1-VLP. Gardasil 9 targets nine HPV types andcomparing to the other two vaccines it is the most effective at preventing the development of preinvasive cervical cancer. WHO recommends administering them to girls aged 9 to 14 in a two-dose schedule or from 15 years of age in a three-dose schedule. The side effects of the above-mentioned vaccines were mostly associated with a cutaneous reactions around the site of injection (pain, redness, swelling), and some people also experienced systemic symptoms such as a headache, a fever, vomiting, a dizziness, muscle pain and a diarrhea. The following article is an analysis of the current knowledge on the effectiveness and safety of prophylactic HPV vaccines based on publications available in the Pubmed and Google Scholar databases.
References
Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2021 Jan 20;8:552028. doi: 10.3389/fpubh.2020.552028. PMID: 33553082; PMCID: PMC7855977.
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664-670. doi: 10.1002/ijc.30716. Epub 2017 Jun 8. PMID: 28369882; PMCID: PMC5520228.
Crusz SM, El-Shakankery K, Miller RE. Targeting HPV in gynaecological cancers - Current status, ongoing challenges and future directions. Womens Health (Lond). 2020 Jan-Dec;16:1745506520961709. doi: 10.1177/1745506520961709. PMID: 33296284; PMCID: PMC7731692.
Wakeham K, Kavanagh K. The burden of HPV-associated anogenital cancers. Curr Oncol Rep. 2014 Sep;16(9):402. doi: 10.1007/s11912-014-0402-4. PMID: 25118645.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. PMID: 23199955.
Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med. 2016;67:91-101. doi: 10.1146/annurev-med-051914-021907. Epub 2015 Aug 26. PMID: 26332002; PMCID: PMC5242186.
Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013 May;35(5):747-55. doi: 10.1002/hed.22015. Epub 2012 Jan 20. PMID: 22267298.
Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2014 Jun;26:13-21. doi: 10.1016/j.semcancer.2013.11.002. Epub 2013 Dec 4. PMID: 24316445.
Pastrana DV, Peretti A, Welch NL, Borgogna C, Olivero C, Badolato R, Notarangelo LD, Gariglio M, FitzGerald PC, McIntosh CE, Reeves J, Starrett GJ, Bliskovsky V, Velez D, Brownell I, Yarchoan R, Wyvill KM, Uldrick TS, Maldarelli F, Lisco A, Sereti I, Gonzalez CM, Androphy EJ, McBride AA, Van Doorslaer K, Garcia F, Dvoretzky I, Liu JS, Han J, Murphy PM, McDermott DH, Buck CB. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. mSphere. 2018 Dec 12;3(6):e00645-18. doi: 10.1128/mSphereDirect.00645-18. PMID: 30541782; PMCID: PMC6291628.
Brianti P, De Flammineis E, Mercuri SR. Review of HPV-related diseases and cancers. New Microbiol. 2017 Apr;40(2):80-85. Epub 2017 Apr 3. PMID: 28368072.
Athanasiou A, Bowden S, Paraskevaidi M, Fotopoulou C, Martin-Hirsch P, Paraskevaidis E, Kyrgiou M. HPV vaccination and cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2020 May;65:109-124. doi: 10.1016/j.bpobgyn.2020.02.009. Epub 2020 Mar 5. PMID: 32284298.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. PMID: 10451482.
Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. Ann Ig. 2018 Jul-Aug;30(4 Supple 1):28-32. doi: 10.7416/ai.2018.2231. PMID: 30062377.
Hampson IN, Oliver AW, Hampson L. Potential Effects of Human Papillomavirus Type Substitution, Superinfection Exclusion and Latency on the Efficacy of the Current L1 Prophylactic Vaccines. Viruses. 2020 Dec 24;13(1):22. doi: 10.3390/v13010022. PMID: 33374445; PMCID: PMC7823767.
Massimo Tommasino, The human papillomavirus family and its role in carcinogenesis,Seminars in Cancer Biology, Volume 26,2014,Pages 13-21,ISSN 1044-579X, https://doi.org/10.1016/j.semcancer.2013.11.002.
Christina Schellenbacher, Richard B.S. Roden, Reinhard Kirnbauer, Developments in L2-based human papillomavirus (HPV) vaccines,Virus Research, Volume 231, 2017, Pages 166-175, ISSN 0168-1702,
https://doi.org/10.1016/j.virusres.2016.11.020.
H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat. Rev. Cancer, 2 (2002), pp. 342-350
Saei Ghare Naz M, Kariman N, Ebadi A, Ozgoli G, Ghasemi V, Rashidi Fakari F. Educational Interventions for Cervical Cancer Screening Behavior of Women: A Systematic Review. Asian Pac J Cancer Prev. 2018 Apr 25;19(4):875-884. doi: 10.22034/APJCP.2018.19.4.875. PMID: 29693331; PMCID: PMC6031778.
Shen Y, Xia J, Li H, Xu Y, Xu S. Human papillomavirus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women. BMC Womens Health. 2021 Feb 25;21(1):80. doi: 10.1186/s12905-021-01217-4. PMID: 33632179; PMCID: PMC7905912.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993 Apr;12(2):186-92. PMID: 8463044.
Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience. 2015 Apr 29;9:526. doi: 10.3332/ecancer.2015.526. PMID: 25987895; PMCID: PMC4431404.
Yadav R, Zhai L, Tumban E. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018. PMID: 31877975; PMCID: PMC7019592.
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC, Shih YT, Walter LC, Kim JJ, Andrews KS, DeSantis CE, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC, Smith RA. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020 Sep;70(5):321-346. doi: 10.3322/caac.21628. Epub 2020 Jul 30. PMID: 32729638.
Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health. 2020 Apr;5(4):e213-e222. doi: 10.1016/S2468-2667(20)30006-2. Epub 2020 Feb 10. PMID: 32057315; PMCID: PMC8715100.
Fokom Domgue J, Chido-Amajuoyi OG, Yu RK, Shete S. Beliefs About HPV Vaccine's Success at Cervical Cancer Prevention Among Adult US Women. JNCI Cancer Spectr. 2019 Aug 27;3(4):pkz064. doi: 10.1093/jncics/pkz064. PMID: 32280919; PMCID: PMC6901081.
Schmuhl NB, Mooney KE, Zhang X, Cooney LG, Conway JH, LoConte NK. No association between HPV vaccination and infertility in U.S. females 18-33 years old. Vaccine. 2020 May 19;38(24):4038-4043. doi: 10.1016/j.vaccine.2020.03.035. Epub 2020 Apr 3. PMID: 32253100; PMCID: PMC7255493.
Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225. PMID: 29145648; PMCID: PMC6279277.
Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med. 2010 Jul;10(50):7-17. PMID: 20670593.
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med. 2015 Apr 3;4(4):614-33. doi: 10.3390/jcm4040614. PMID: 26239350; PMCID: PMC4470159.
Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2012 Dec;17(4):469-92. doi: 10.1517/14728214.2012.744393. Epub 2012 Nov 19. PMID: 23163511; PMCID: PMC3786409.
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018 Jun;5:46-58. doi: 10.1016/j.pvr.2017.12.006. Epub 2017 Dec 19. PMID: 29277575; PMCID: PMC5887015.
Vonsky MS, Runov AL, Gordeychuk IV, Isaguliants MG. Therapeutic Vaccines Against Human Papilloma Viruses: Achievements and Prospects. Biochemistry (Mosc). 2019 Jul;84(7):800-816. doi: 10.1134/S0006297919070101. PMID: 31509730.
Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991 Nov;185(1):251-7. doi: 10.1016/0042-6822(91)90772-4. PMID: 1656586.
Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180-4. doi: 10.1073/pnas.89.24.12180. PMID: 1334560; PMCID: PMC50722.
Mitchell TC, Casella CR. No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines. Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17. PMID: 28728074; PMCID: PMC5626597.
Paz-Zulueta M, Álvarez-Paredes L, Rodríguez Díaz JC, Parás-Bravo P, Andrada Becerra ME, Rodríguez Ingelmo JM, Ruiz García MM, Portilla J, Santibañez M. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer. 2018 Jan 30;18(1):112. doi: 10.1186/s12885-018-4033-2. PMID: 29382323; PMCID: PMC5791190.
Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15;63(4):519-27. doi: 10.1093/cid/ciw354. Epub 2016 May 26. PMID: 27230391; PMCID: PMC4967609.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3;364(5):401-11. doi: 10.1056/NEJMoa0909537. Erratum in: N Engl J Med. 2011 Apr 14;364(15):1481. PMID: 21288094; PMCID: PMC3495065.
Schlecht NF, Masika M, Diaz A, Nucci-Sack A, Salandy A, Pickering S, Strickler HD, Shankar V, Burk RD. Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine. JAMA Netw Open. 2019 Oct 2;2(10):e1914031. doi: 10.1001/jamanetworkopen.2019.14031. PMID: 31651968; PMCID: PMC6822084.
Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, Bastow B, Webster-Cyriaque J, Feng Q, Dragavon J, Coombs RW, Presti RM, Saah A, Cranston RD. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018 Oct 15;67(9):1339-1346. doi: 10.1093/cid/ciy274. PMID: 29659751; PMCID: PMC6186857.
Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009 Oct;5(10):696-704. doi: 10.4161/hv.5.10.9515. Epub 2009 Oct 1. PMID: 19855170.
Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017 Jul;146(1):196-204. doi: 10.1016/j.ygyno.2017.04.004. Epub 2017 Apr 22. Erratum in: Gynecol Oncol. 2017 Nov;147(2):489. PMID: 28442134.
Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22. PMID: 22920953.
Schwarz TF, Huang LM, Valencia A, Panzer F, Chiu CH, Decreux A, Poncelet S, Karkada N, Folschweiller N, Lin L, Dubin G, Struyf F. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother. 2019;15(7-8):1970-1979. doi: 10.1080/21645515.2019.1625644. Epub 2019 Jul 17. PMID: 31268383; PMCID: PMC6746471.
Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. PMID: 23873171; PMCID: PMC3714284.
Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front Immunol. 2020 Feb 18;11:188. doi: 10.3389/fimmu.2020.00188. PMID: 32133000; PMCID: PMC7040023.
Saadeh K, Park I, Gargano JW, Whitney E, Querec TD, Hurley L, Silverberg M. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States. Vaccine. 2020 Jan 3;38(1):39-45. doi: 10.1016/j.vaccine.2019.09.103. Epub 2019 Oct 11. PMID: 31611099.
Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Res. 2016 Jun;130:101-9. doi: 10.1016/j.antiviral.2016.03.016. Epub 2016 Apr 1. PMID: 27040313.
Buchanan TR, Graybill WS, Pierce JY. Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccin Immunother. 2016 Jun 2;12(6):1352-6. doi: 10.1080/21645515.2016.1147634. Epub 2016 Feb 22. PMID: 26901390; PMCID: PMC4964646.
Guevara AM, Suarez E, Victoria A, Ngan HY, Hirschberg AL, Fedrizzi E, Bautista O, Shields C, Joshi A, Luxembourg A. Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. Hum Vaccin Immunother. 2019;15(1):141-145. doi: 10.1080/21645515.2018.1514227. Epub 2018 Sep 27. PMID: 30261146; PMCID: PMC6363163.
Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014 Nov-Dec;18(6):651-9. doi: 10.1016/j.bjid.2014.02.005. Epub 2014 Apr 27. PMID: 24780368; PMCID: PMC9425215.
Martínez-Lavín M, Amezcua-Guerra L. Erratum to: Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clin Rheumatol. 2017 Oct;36(10):2397. doi: 10.1007/s10067-017-3782-7. Erratum for: Clin Rheumatol. 2017 Jul 20;: PMID: 28755028.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 Jun 30;369(9580):2161-2170. doi: 10.1016/S0140-6736(07)60946-5. Erratum in: Lancet. 2007 Oct 20;370(9596):1414. PMID: 17602732.
Safety of HPV Vaccines. [(accessed on 23 October 2021)]. Available online: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety
HPV Vaccine Safety and Effectiveness. [(accessed on 23 October 2021)]; Available online: https://www.cdc.gov/vaccines/vpd/hpv/hcp/safety-effectiveness.html
Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub ES. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26;29(46):8279-84. doi: 10.1016/j.vaccine.2011.08.106. Epub 2011 Sep 9. PMID: 21907257.
Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009 May;5(5):332-40. doi: 10.4161/hv.5.5.7211. Epub 2009 May 20. PMID: 19221517.
Martínez-Lavín M. Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination. J Clin Rheumatol. 2014 Oct;20(7):392-3. doi: 10.1097/RHU.0000000000000165. PMID: 25275771.
Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013 Oct 9;347:f5906. doi: 10.1136/bmj.f5906. PMID: 24108159; PMCID: PMC3805482.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Michał Paluch, Michał Tomkiewicz , Paweł Olko , Jakub Radulski, Piotr Sałata , Magda Żuchnik , Hugo Szczuraszek , Paulina Szczuraszek , Agnieszka Rybkowska, Julia Tomkiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 463
Number of citations: 0